Company: CERO
Filing Date: 2025-05-27
Form Type: POS AM
Source: 0001213900-25-047469
Chunk: 126

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-05-27
Form: POS AM
Chunk 126
---
 any delays in regulatory review                             
 and approval of product candidates in clinical development; |

| ● | the timing and cost of, and                                                                                    
 level of investment in, R&D activities relating to our product candidates, which may change from time to time; |

| ● | the cost of manufacturing our                                                                                    
 product candidates, which may vary depending on FDA guidelines and requirements, and the quantity of production; |

| ● | our ability to obtain additional       
 funding to develop product candidates; |

| ● | expenditures that our will or                                                   
 may incur to acquire or develop additional product candidates and technologies; |

| ● | the level of demand for our                                                     
 product candidates, should they receive approval, which may vary significantly; |

| ● | potential side effects of our                                                                                          
 product candidates that could delay or prevent commercialization or cause an approved drug to be taken off the market; |

| ● | the ability of patients or healthcare                                                                
 providers to obtain coverage of or sufficient reimbursement for our product candidates, if approved; |

| ● | our dependency on third-party                                  
 manufacturers to supply or manufacture our product candidates; |

| ● | our ability to establish an                                                    
 effective sales, marketing and distribution infrastructure in a timely manner; |

| ● | market acceptance of our product                                                          
 candidates, if approved, and our ability to forecast demand for those product candidates; |

| ● | our ability to receive approval                                    
 and commercialize product candidates outside of the United States; |

| ● | our ability to establish and                              
 maintain collaborations, licensing or other arrangements; |

| ● | our ability and third parties’                     
 abilities to protect intellectual property rights; |

| ● | costs related to and outcomes              
 of potential litigation or other disputes; |

| ● | our ability to adequately support 
 future growth;                    |

| ● | our ability to attract and retain                 
 key personnel to manage our business effectively; |

| ● | potential liabilities associated 
 with hazardous materials;        |

| ● | our ability to maintain adequate 
 insurance policies; and          |

| ● | future accounting pronouncements       
 or changes in our accounting policies. |

The cumulative effect of such factors could result in large fluctuations and unpredictability in quarterly and annual operating results. As a result, comparing operating results on a period-to-period basis may not be meaningful. Investors should not rely on past results as an indication of future performance. This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall